Company profile
Pulmatrix, Inc.
NASDAQ:PULMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ITRACONAZOLE | phase2 | — | 20 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02198963 | phase1 | completed | 2014-07-01 | 2014-08-01 | Pulmatrix Inc. | 21 Day Cumulative Skin Irritation of RUT058-60 |
| NCT02671825 | phase1 | completed | 2016-01-01 | 2016-03-01 | Pulmatrix Inc. | A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects |
| NCT04759807 | phase1 | completed | 2021-01-04 | 2021-12-02 | Pulmatrix Inc. | A Phase 1b Study of PUR1800 in Patients With COPD |
| NCT02280395 | phase1_2 | terminated | 2014-10-01 | 2015-06-01 | Pulmatrix Inc. | A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 |
| NCT01543191 | phase1 | completed | 2012-02-01 | 2012-12-01 | Pulmatrix Inc. | A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis |
FDA applications (0)
No records yet.